Jamshid Maddahi1, Joel Lazewatsky2, James E Udelson3, Daniel S Berman4, Rob S B Beanlands5, Gary V Heller6, Timothy M Bateman7, Juhani Knuuti8, Cesare Orlandi2. 1. Division of Nuclear Medicine, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California-Los Angeles, Los Angeles, California; Division of Cardiology, Department of Medicine, David Geffen School of Medicine, University of California-Los Angeles, Los Angeles, California. Electronic address: jmaddahi@gmail.com. 2. Lantheus Medical Imaging, North Billerica, Massachusetts. 3. Tufts Medical Center, Boston, Massachusetts. 4. Cedars-Sinai Medical Center, Los Angeles, California. 5. University of Ottawa Heart Institute, Ottawa, Ontario, Canada. 6. Morristown Medical Center, Morristown, New Jersey. 7. Mid America Heart Institute, Saint Luke's Hospital, Kansas City, Missouri. 8. Turku University, Turku, Finland.
Abstract
BACKGROUND: Fluorine-18 flurpiridaz is a novel positron emission tomography (PET) myocardial perfusion imaging tracer. OBJECTIVES: This study sought to assess the diagnostic efficacy of flurpiridaz PET versus technetium-99m-labeled single photon emission computed tomography SPECT for the detection and evaluation of coronary artery disease (CAD), defined as ≥50% stenosis by quantitative invasive coronary angiography (ICA). Flurpiridaz safety was also evaluated. METHODS: In this phase III prospective multicenter clinical study, 795 patients with known or suspected CAD from 72 clinical sites in the United States, Canada, and Finland were enrolled. A total of 755 patients were evaluable, and the mean age was 62.3 ± 9.5 years, 31% were women, 55% had body mass index ≥30 kg/m2, and 71% had pharmacological stress. Patients underwent 1-day rest-stress (pharmacological or exercise) flurpiridaz PET and 1- or 2-day rest-stress Tc-99m-labeled SPECT and ICA. Images were read by 3 experts blinded to clinical and ICA data. RESULTS: Sensitivity of flurpiridaz PET (for detection of ≥50% stenosis by ICA) was 71.9% (95% confidence interval [CI]: 67.0% to 76.3%), significantly (p < 0.001) higher than SPECT (53.7% [95% CI: 48.5% to 58.8%]), while specificity did not meet the prespecified noninferiority criterion (76.2% [95% CI: 71.8% to 80.1%] vs. 86.6% [95% CI: 83.2% to 89.8%]; p = NS). Receiver-operating characteristic curve analysis demonstrated superior discrimination of CAD by flurpiridaz PET versus SPECT in the overall population, in women, obese patients, and patients undergoing pharmacological stress testing (p < 0.001 for all). Flurpiridaz PET was superior to SPECT for defect size (p < 0.001), image quality (p < 0.001), diagnostic certainty (p < 0.001), and radiation exposure (6.1 ± 0.4 mSv vs. 13.4 ± 3.2 mSv; p < 0.001). Flurpiridaz PET was safe and well tolerated. CONCLUSIONS: Flurpiridaz PET myocardial perfusion imaging shows promise as a new tracer for CAD detection and assessment of women, obese patients, and patients undergoing pharmacological stress testing. A second phase III Food and Drug Administration trial is ongoing. (A Phase 3 Multi-center Study to Assess PET Imaging of Flurpiridaz F 18 Injection in Patients with CAD; NCT01347710).
BACKGROUND:Fluorine-18 flurpiridaz is a novel positron emission tomography (PET) myocardial perfusion imaging tracer. OBJECTIVES: This study sought to assess the diagnostic efficacy of flurpiridaz PET versus technetium-99m-labeled single photon emission computed tomography SPECT for the detection and evaluation of coronary artery disease (CAD), defined as ≥50% stenosis by quantitative invasive coronary angiography (ICA). Flurpiridaz safety was also evaluated. METHODS: In this phase III prospective multicenter clinical study, 795 patients with known or suspected CAD from 72 clinical sites in the United States, Canada, and Finland were enrolled. A total of 755 patients were evaluable, and the mean age was 62.3 ± 9.5 years, 31% were women, 55% had body mass index ≥30 kg/m2, and 71% had pharmacological stress. Patients underwent 1-day rest-stress (pharmacological or exercise) flurpiridaz PET and 1- or 2-day rest-stress Tc-99m-labeled SPECT and ICA. Images were read by 3 experts blinded to clinical and ICA data. RESULTS: Sensitivity of flurpiridaz PET (for detection of ≥50% stenosis by ICA) was 71.9% (95% confidence interval [CI]: 67.0% to 76.3%), significantly (p < 0.001) higher than SPECT (53.7% [95% CI: 48.5% to 58.8%]), while specificity did not meet the prespecified noninferiority criterion (76.2% [95% CI: 71.8% to 80.1%] vs. 86.6% [95% CI: 83.2% to 89.8%]; p = NS). Receiver-operating characteristic curve analysis demonstrated superior discrimination of CAD by flurpiridaz PET versus SPECT in the overall population, in women, obesepatients, and patients undergoing pharmacological stress testing (p < 0.001 for all). Flurpiridaz PET was superior to SPECT for defect size (p < 0.001), image quality (p < 0.001), diagnostic certainty (p < 0.001), and radiation exposure (6.1 ± 0.4 mSv vs. 13.4 ± 3.2 mSv; p < 0.001). Flurpiridaz PET was safe and well tolerated. CONCLUSIONS:Flurpiridaz PET myocardial perfusion imaging shows promise as a new tracer for CAD detection and assessment of women, obesepatients, and patients undergoing pharmacological stress testing. A second phase III Food and Drug Administration trial is ongoing. (A Phase 3 Multi-center Study to Assess PET Imaging of Flurpiridaz F 18 Injection in Patients with CAD; NCT01347710).
Authors: Susan Bengs; Geoffrey I Warnock; Catherine Gebhard; Ahmed Haider; Angela Portmann; Nidaa Mikail; Alexia Rossi; Hazem Ahmed; Dominik Etter; Valerie Treyer; Livio Gisler; Stefanie K Pfister; Caitlin V M L Jie; Alexander Meisel; Claudia Keller; Steven H Liang; Roger Schibli; Linjing Mu; Ronny R Buechel; Philipp A Kaufmann; Simon M Ametamey Journal: J Nucl Cardiol Date: 2022-04-28 Impact factor: 5.952
Authors: Nidaa Mikail; Alexia Rossi; Susan Bengs; Ahmed Haider; Barbara E Stähli; Angela Portmann; Alessio Imperiale; Valerie Treyer; Alexander Meisel; Aju P Pazhenkottil; Michael Messerli; Vera Regitz-Zagrosek; Philipp A Kaufmann; Ronny R Buechel; Cathérine Gebhard Journal: Eur J Nucl Med Mol Imaging Date: 2022-08-17 Impact factor: 10.057
Authors: Yuka Otaki; Serge D Van Kriekinge; Chih-Chun Wei; Paul Kavanagh; Ananya Singh; Tejas Parekh; Marcelo Di Carli; Jamshid Maddahi; Arkadiusz Sitek; Christopher Buckley; Daniel S Berman; Piotr J Slomka Journal: Eur J Nucl Med Mol Imaging Date: 2021-12-30 Impact factor: 10.057
Authors: Jamieson M Bourque; Christopher A Hanson; Denis Agostini; Timothy M Bateman; Jeroen J Bax; Rob S B Beanlands; Daniel S Berman; Ernest V Garcia; Gary V Heller; Juhani Knuuti; Nagara Tamaki; James E Udelson; Jamshid Maddahi Journal: J Nucl Cardiol Date: 2021-01-31 Impact factor: 5.952
Authors: René R Sevag Packard; C David Cooke; Kenneth F Van Train; John R Votaw; James W Sayre; Joel L Lazewatsky; Kelly M Champagne; Cesare Orlandi; Ernest V Garcia; Jamshid Maddahi Journal: J Nucl Cardiol Date: 2020-09-07 Impact factor: 5.952